In conclusion, we showed that patients with NAFLD have a different immune response to severe COVID-19, with IL-6, IL-8, IL-10, and CXCL10 as a possible culprits of an uncontrolled inflammation associated with disease severity in this group of patients. This evidence concerns the gene CXCL10 and metabolic dysfunction-associated steatotic liver disease.